このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Sarepta Therapeutics 将来の成長

Future 基準チェック /66

Sarepta Therapeutics利益と収益がそれぞれ年間44.9%と24.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に50.6% 42.6%なると予測されています。

主要情報

44.1%

収益成長率

41.6%

EPS成長率

Biotechs 収益成長	28.4%
収益成長率	23.6%
将来の株主資本利益率	50.6%
アナリストカバレッジ	Good
最終更新日	20 Sep 2024

今後の成長に関する最新情報

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

May 05

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02

Recent updates

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Jul 05

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Jun 17

Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

May 08

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

May 05

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Apr 15

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Apr 11

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Feb 06

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Jan 22

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 10

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Dec 20

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Nov 29

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Aug 08

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Apr 30

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Jan 17

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Sep 29

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Sep 12

Sarepta says FDA lifted clinical hold on Duchenne candidate

Sep 06

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Aug 08

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Jul 29

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

May 09

業績と収益の成長予測

NasdaqGS:SRPT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,854	1,504	1,367	1,589	11
12/31/2025	3,106	1,009	1,181	1,289	15
12/31/2024	1,737	130	-287	11	14
6/30/2024	1,505	47	-528	-396	N/A
3/31/2024	1,403	17	-552	-534	N/A
12/31/2023	1,243	-536	-486	-501	N/A
9/30/2023	1,105	-691	-512	-539	N/A
6/30/2023	1,003	-908	-432	-489	N/A
3/31/2023	976	-1,115	-470	-434	N/A
12/31/2022	933	-703	-358	-325	N/A
9/30/2022	876	-716	-289	-262	N/A
6/30/2022	835	-507	-348	-322	N/A
3/31/2022	766	-357	-285	-364	N/A
12/31/2021	702	-419	-382	-443	N/A
9/30/2021	646	-486	-551	-588	N/A
6/30/2021	600	-634	-681	-702	N/A
3/31/2021	573	-704	-795	-701	N/A
12/31/2020	540	-554	133	107	N/A
9/30/2020	495	-601	155	118	N/A
6/30/2020	450	-530	342	289	N/A
3/31/2020	407	-656	373	318	N/A
12/31/2019	381	-715	-516	-456	N/A
9/30/2019	365	-620	-478	-415	N/A
6/30/2019	345	-570	-536	-461	N/A
3/31/2019	323	-403	-567	-499	N/A
12/31/2018	301	-362	-450	-389	N/A
9/30/2018	274	-245	-345	-297	N/A
6/30/2018	241	-216	-277	-242	N/A
3/31/2018	203	-170	N/A	-210	N/A
12/31/2017	155	-51	N/A	-232	N/A
9/30/2017	103	-115	N/A	-282	N/A
6/30/2017	57	-124	N/A	-285	N/A
3/31/2017	22	-123	N/A	-243	N/A
12/31/2016	5	-267	N/A	-246	N/A
9/30/2016	1	-243	N/A	-196	N/A
6/30/2016	1	-239	N/A	-182	N/A
3/31/2016	1	-218	N/A	-167	N/A
12/31/2015	1	-220	N/A	-149	N/A
9/30/2015	0	-200	N/A	-144	N/A
6/30/2015	1	-177	N/A	-133	N/A
3/31/2015	4	-169	N/A	-144	N/A
12/31/2014	10	-136	N/A	-129	N/A
9/30/2014	12	-100	N/A	-121	N/A
6/30/2014	15	-113	N/A	-105	N/A
3/31/2014	16	-98	N/A	-78	N/A
12/31/2013	14	-112	N/A	-65	N/A
9/30/2013	19	-165	N/A	-54	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SRPTの予測収益成長率 (年間44.9% ) は貯蓄率 ( 2.5% ) を上回っています。

収益対市場: SRPTの収益 ( 44.9% ) はUS市場 ( 15.2% ) よりも速いペースで成長すると予測されています。

高成長収益: SRPTの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: SRPTの収益 ( 24.2% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: SRPTの収益 ( 24.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SRPTの自己資本利益率は、3年後には非常に高くなると予測されています ( 50.6 %)。

Sarepta Therapeutics 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Consensus EPS estimates increase by 17%

Consensus revenue estimates fall by 12%

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025

Price target increased by 12% to US$187

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

The Play On Sarepta Therapeutics

Sarepta Therapeutics Muscles Up In DMD Race

Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors

Executive VP & CFO recently sold US$822k worth of stock

Executive VP & CFO notifies of intention to sell stock

Consensus EPS estimates increase by 17%

Insider recently bought US$5.0m worth of stock

Consensus revenue estimates fall by 12%

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025

Sarepta Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Executive VP exercised options and sold US$2.3m worth of stock

Price target increased by 12% to US$187

Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Now 21% undervalued after recent price drop

Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Board Member notifies of intention to sell stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 8.0% to US$162

Sarepta Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Forecast to breakeven in 2024

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Independent Chairwoman exercised options to buy US$1.2m worth of stock.

Independent Director recently bought US$3.9m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Price target decreased by 21% to US$143

Sarepta Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

No longer forecast to breakeven

Insider recently bought US$3.7m worth of stock

Consensus estimates of losses per share improve by 22%

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Board Member notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sarepta Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Sarepta Therapeutics, Inc. Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Consensus EPS estimates upgraded to US$3.68 loss

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 13%

Price target increased by 11% to US$167

Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Independent Chairwoman exercised options to buy US$2.6m worth of stock.

Sarepta Therapeutics Announces That U.S. FDA Has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’S Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

Insider recently sold US$94k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations